Literature DB >> 11469724

Hepatic cytochrome P450 regulation in disease states.

P Y Cheng1, E T Morgan.   

Abstract

Hepatic cytochrome P450 (P450) enzyme activities and gene expression can be profoundly altered in disease states. In general the levels of affected hepatic P450 enzymes are depressed by diseases, causing potential and documented impairment of drug clearance and clinical drug toxicity. However, modulation of P450s is enzyme selective and this selectivity differs among different diseases. This review will concentrate on regulation of P450s in diabetes, obesity and infectious and inflammatory disease, conditions that affect millions of people worldwide every day.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11469724     DOI: 10.2174/1389200013338676

Source DB:  PubMed          Journal:  Curr Drug Metab        ISSN: 1389-2002            Impact factor:   3.731


  32 in total

Review 1.  Effect of diabetes mellitus on pharmacokinetic and pharmacodynamic properties of drugs.

Authors:  Miroslav Dostalek; Fatemeh Akhlaghi; Martina Puzanovova
Journal:  Clin Pharmacokinet       Date:  2012-08-01       Impact factor: 6.447

2.  Turpentine oil induced inflammation decreases absorption and increases distribution of phenacetin without altering its elimination process in rats.

Authors:  V G N V Prasad; Ch Vivek; P Anand Kumar; P Ravi Kumar; G S Rao
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2013-12-20       Impact factor: 2.441

3.  Concentration of tacrolimus and major metabolites in kidney transplant recipients as a function of diabetes mellitus and cytochrome P450 3A gene polymorphism.

Authors:  Shripad D Chitnis; Ken Ogasawara; Björn Schniedewind; Reginald Y Gohh; Uwe Christians; Fatemeh Akhlaghi
Journal:  Xenobiotica       Date:  2013-01-02       Impact factor: 1.908

4.  Effect of the ethinylestradiol/levonorgestrel combined oral contraceptive on the activity of cytochrome P4503A in obese women.

Authors:  Alison Edelman; Myrna Munar; Miriam R Elman; Dennis Koop; Ganesh Cherala
Journal:  Br J Clin Pharmacol       Date:  2012-09       Impact factor: 4.335

5.  Pharmacokinetics of lidocaine and its metabolite in peridural anesthesia administered to pregnant women with gestational diabetes mellitus.

Authors:  Elaine Christine Dantas Moisés; Luciana de Barros Duarte; Ricardo de Carvalho Cavalli; Maria Paula Marques; Vera Lúcia Lanchote; Geraldo Duarte; Sérgio Pereira da Cunha
Journal:  Eur J Clin Pharmacol       Date:  2008-08-06       Impact factor: 2.953

6.  Role of constitutive androstane receptor in Toll-like receptor-mediated regulation of gene expression of hepatic drug-metabolizing enzymes and transporters.

Authors:  Pranav Shah; Tao Guo; David D Moore; Romi Ghose
Journal:  Drug Metab Dispos       Date:  2013-11-05       Impact factor: 3.922

7.  Helicobacter pylori infection is associated with greater impairment of cytochrome P-450 liver metabolic activity in anti-HCV positive cirrhotic patients.

Authors:  Edoardo Giannini; Alberto Fasoli; Federica Botta; Paola Romagnoli; Federica Malfatti; Bruno Chiarbonello; Mario Mamone; Vincenzo Savarino; Roberto Testa
Journal:  Dig Dis Sci       Date:  2003-04       Impact factor: 3.199

8.  Blood and plasma pharmacokinetics of ciclosporin in diabetic kidney transplant recipients.

Authors:  Anisha E Mendonza; Reginald Y Gohh; Fatemeh Akhlaghi
Journal:  Clin Pharmacokinet       Date:  2008       Impact factor: 6.447

9.  Constitutive androstane receptor mediates the induction of drug metabolism in mouse models of type 1 diabetes.

Authors:  Bingning Dong; Mohammed Qatanani; David D Moore
Journal:  Hepatology       Date:  2009-08       Impact factor: 17.425

10.  Influence of overt diabetes mellitus on cyclosporine pharmacokinetics in a canine model.

Authors:  Khalid M Alkharfy
Journal:  Exp Diabetes Res       Date:  2009-10-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.